Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Mitoxantrone × 90 days × Clear all

Phase

Phase 2 4 Phase 3 3 Phase 1 2 Phase 4 1 Phase 2/3 1 Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Thyroid Cancer, Papillary 1

Interventions

Specimen Handling 5 Dexamethasone 5 Rituximab 4 Prednisone 4 Cisplatin 4 Carboplatin 4 darolutamide 3 Vincristine 3 Tobacco Use Cessation Devices 3 Magnetic Resonance Spectroscopy 3 Letrozole 3 Injections 3 Hydromorphone 3 Bevacizumab 3 trametinib 2 ribociclib 2 pirtobrutinib 2 pembrolizumab 2 obinutuzumab 2 gadolinium ethoxybenzyl DTPA 2 enzalutamide 2 enfortumab vedotin 2 dabrafenib 2 Watchful Waiting 2 Thalidomide 2 Standard of Care 2 Propofol 2 Paclitaxel 2 Oxaliplatin 2 Observation 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07354698 2026-01-21

MHI

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 4 Not yet recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡